Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on AdAlta.
RELATED STOCKHEAD STORIES
News
Lunch Wrap: It’s a sea of red on the ASX; staples and banks battered
Long Shortz
Long Shortz with AdAlta: The East to West vision for immunotherapy
Health & Biotech
AdAlta prioritises ‘East to West’ cellular immunotherapy strategy to drive value creation
Health & Biotech
AdAlta boosts leadership in Q2 FY25 to support growth strategy
Tony's Takeaway
Tony’s Takeaway: New year nuggets for biotech-hungry investors
Stockhead TV
Road to 2025: AdAlta’s push to advance lead drug AD-214 for deadly IPF
WTF?!
WTF with 1AD: New approach to treating fibrosis with lead i-body drug candidate
News
ASX Lunch Wrap: Curve ball thrown as new bank levy bites; Alderan jumps on US copper hit
Long Shortz
Long Shortz with AdAlta: Growing in confidence every day for fibrotic medical treatments
Health & Biotech
AdAlta secures top talent to lead AdCella and AdSolis as boost in clinical activity looms
News
ASX Small Caps Lunch Wrap: ASX up, and things are pretty quiet for a Wednesday
Stockhead TV
Tony’s Takeaway: A second helping of biotech picks
Long Shortz
Long Shortz with AdAlta: Global health experts recruited for idiopathic pulmonary fibrosis drug
Health & Biotech
AdAlta forms clinical advisory board to advance IPF drug candidate
News
ASX Small Caps Lunch Wrap: Geopolitical turmoil still suppressing markets… buy the dip?
News
Closing Bell: ASX up 0.22pc after slow start; iron ore miners, REA weigh on market
Health & Biotech
